Treatment
Pain relief is administered concomitantly to the treatment of the primary disease causing tenesmus. See also
Encopresis
Constipation
Fecal incontinence

References
External links

MedlinePlus Encyclopedia: 003131
On September 29, 2011, the FDA issued new guidance with regard to the DESI category. This effectively disallowed any new DESI formulations to enter the market. The FDA also has stated that DESI drugs do not have any therapeutic equivalent drugs listed in the “Orange Book”. In their description of therapeutic equivalence, the FDA specifically cites Donnatal®. Therefore, any so-called generic drugs on the market with similar formulation to DESI drugs, are considered illegal drugs as the FDA has not reviewed their composition or therapeutic equivalence. Donnatal, although containing phenobarbital, is exempt from the Controlled Substances Act due to the belladonna alkaloids present in the formulation. References
External links
"Donnatal Extended Release Tablet Information". Archived from the original on 2008-12-27.